All In Biotech

Free tool

FAERS Monitor: Opsynvi

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 218490 or its brand name (Opsynvi, Macitentan, Tadalafil). Reports on generic versions are filed under their own applications.

Reports

25

Serious

17

68% of reports

Hospitalization

13

Death reported

2

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • dyspnoea4
  • cough3
  • death3
  • diarrhoea3
  • chest pain2
  • drug intolerance2
  • hypotension2
  • pneumonia2
  • adverse event1
  • angiopathy1
  • arthritis1
  • atrial fibrillation1
  • back pain1
  • blood pressure increased1
  • breast pain1

Reports by year received

View as table
YearReports
20243
202516
20266

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,134 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
angiopathy1150.122.037
breast pain178.911.619
drug intolerance217.44.617
arthritis110.71.62
adverse event19.11.31
chest pain29.12.48
coughSignal39.03.114
atrial fibrillation18.61.31
hypotension28.42.27
dyspnoeaSignal45.92.412
blood pressure increased15.50.81
pneumonia25.21.43
diarrhoeaSignal33.91.44
back pain13.60.50
death32.91.02

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.